Abstract
There are currently a number of licensed azole antifungal drugs; however; only 4 (namely, fluconazole, itraconazole, posa- conazole, and voriconazole) are used frequently in a clinical setting for prophylaxis or treatment of systemic fungal infections. In this article, we review the pharmacokinetic interactions of these azole antifungal drugs with other coadministered agents. We describe these (2-way) interactions and the extent to which metabolic pathways and/or other supposed mechanisms are involved in these interactions. This article provides an overview of all published drug-drug interactions in humans (either healthy volunteers or patients), and on the basis of these findings, we have developed recommendations for managing the specific interactions.
| Original language | English |
|---|---|
| Pages (from-to) | 1441-1458 |
| Number of pages | 18 |
| Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |
| Volume | 48 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 15 May 2009 |
| Externally published | Yes |
Fingerprint
Dive into the research topics of 'Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver